Clinical Trial Update: Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4 [Phase 2]

View source ↗

Summary

MITO END-4 is a Phase 2 trial evaluating Inavolisib for PIK3CA-mutated advanced endometrial cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Inavolisib (Inavolisib)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Endometrial Cancer | Phase 2 | Status: NOT_YET_RECRUITING